We are looking for antibodies which selectively address a specific target or pathway.
Though polyclonal antibodies are not excluded, the initiative focuses primarily on monoclonal antibodies.
To assess your application, we’ll need to review biological information on your antibody (e.g. the species, origin, or clonality) as specified in the submission form on the PartnerYourAntibodies website.
To protect your intellectual property, please submit only non-confidential information, and do not reveal the amino acid sequence or the binding epitope at this stage.
Before asking for confidential data we will sign a Confidential Disclosure Agreement (CDA) with you.
We will assess your antibody’s properties based on its molecular descriptors and biological activity.
- Ideally, your antibody addresses targets or pathways relevant to our core research areas at Bayer.
- In a first step, we will assess your antibody’s molecular descriptors – e.g. the species, origin, clonality, cross-reactivity, or target – which you provided in your application.
- If your innovative project is confirmed in step one, we might want to test your antibody (especially regarding its biological interaction with the target) under a Material Transfer Agreement or to get some more information under a Confidential Disclosure Agreement. We might already provide you reasonable monetary compensation for your effort at this stage.
